MiMARK Diagnostics

mimark.es ↗ ·Barcelona ·Seed

MiMARK Diagnostics is a Barcelona-based women's health diagnostics company and spin-off of the Vall d'Hebron Research Institute (VHIR), founded in January 2021. It develops protein-biomarker-based in vitro diagnostic (IVD) tests from minimally invasive gynaecological fluid samples via its GyLDa platform, led by WomEC/GyLDEC for endometrial cancer detection, which cuts diagnosis from roughly a month to about two days and reduces the need for invasive biopsies. The company is seed-stage, having closed a €4.22M seed round in November 2023 (including a €2.5M EIC Accelerator component) plus a subsequent ~€1M extension; it is headquartered in Barcelona at Parc Científic de Barcelona.

Founded

2021

Founders

Total funds raised

€1.7M

SectorsHealthtech & Bio, Medtech, Diagnostics, Femtech, Deeptech & Hardware Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Antonio Gil-Moreno

CMO & Co-founder

Eva Colás

CSO & Co-founder

Marina Rigau

CEO & Co-founder

Global models 4

InterVenn Biosciences

United States · intervenn.com ↗

Develops protein-biomarker (glycoproteomic) in vitro diagnostic tests, led by an ovarian-cancer test, sold to clinicians and payers like MiMARK's gynaecological-cancer IVDs.

$200MComparable

Daye

United Kingdom · yourdaye.com ↗

Runs a women's-health diagnostics line that tests minimally invasive, tampon-collected gynaecological samples, the same sampling approach as MiMARK's platform.

$80MComparable

NextGen Jane

United States · www.nextgenjane.com ↗

Builds molecular diagnostics for gynaecological conditions such as endometriosis from tampon-collected menstrual samples, a close match to MiMARK's fluid-based gynaecological IVD model.

$40MComparable

Teal Health

United States · www.getteal.com ↗

Offers an FDA-approved at-home self-collection test for cervical-cancer screening, replacing an invasive clinical procedure the way MiMARK aims to cut endometrial biopsies.

$35MComparable